Competition from Other Companies’ Pharmaceuticals and Generic Drugs
First written in FY2016. 17 of 22 entries say "Restated". Latest entry: FY2024.
Kissei Pharmaceutical moved to the "Worse" side of this theme in 2019, 3 years before the typical company in this theme (2022).
The whole theme swung hardest in 2025: 4 of 8 companies on the "Worse" side.
8 other companies' latest entry also says "Restated".
- FY2024RestatedAnnual report
「In addition to competition from other companies’ drugs indicated for the same conditions as the drugs we sell, we face price competition from generic drugs containing the same active ingredients that are launched after the patents for originator drugs expire.」
The potential for competition from other companies’ drugs and generic drugs to affect sales of existing products has been reconfirmed. - FY2024-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
It has been reconfirmed that there have been no material changes in the risk of competition from other companies’ drugs and generic drugs. - FY2023-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
It has been reconfirmed that there have been no material changes in the risk of competition from other companies’ drugs and generic drugs. - FY2023-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
It has been reconfirmed that there have been no material changes in the risk of competition from other companies’ drugs and generic drugs. - FY2023-Q1RestatedAnnual report
「During the three-month period ended 30 June, there were no new risks that management recognizes as having the potential to materially affect the financial position, operating results or cash flows of the consolidated companies, and no material changes to the business risks described in the annual securities report for the previous fiscal year.」
It has been reconfirmed that there have been no material changes in the risk of competition from other companies’ drugs and generic drugs. - FY2022RestatedAnnual report
「In addition to competition from other companies’ drugs indicated for the same conditions as the drugs we sell, we face price competition from generic drugs containing the same active ingredients that are launched after the patents for originator drugs expire. This competition could have a significant impact on sales of existing products.」
The potential impact of competition from other companies’ drugs and generic drugs launched after patent expiry on sales of existing products has been reconfirmed. - FY2022-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
It has been reconfirmed that there have been no material changes in the risk of competition from other companies’ drugs and generic drugs. - FY2022-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
It has been reconfirmed that there have been no material changes in the risk of competition from other companies’ drugs and generic drugs. - FY2021-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
It has been reconfirmed that there have been no material changes in the risk of competition from other companies’ drugs and generic drugs. - FY2021-Q1RestatedAnnual report
「No new business or other risks arose during the three months ended 30 June. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
It has been reconfirmed that there have been no material changes in the risk of competition from other companies’ drugs and generic drugs. - FY2020MaterialisedAnnual report
「As a result, pharmaceutical business sales decreased by ¥10,212 million, or 16.6%, from the previous consolidated fiscal year to ¥51,308 million.」
The impact of competition from other companies’ drugs and generic drugs, including the decline in sales following the launch of generic versions of Urorec, has been reflected in a 16.6% decline in annual sales. - FY2020-Q3MaterialisedAnnual report
「Pharmaceutical business net sales were ¥40,288 million, down 15.5% year on year. Sales of products including the overactive bladder treatment Beova Tablets, the hyperphosphatemia treatments P-TOL Chewable Tablets and P-TOL Granules in Sachets, and the diabetes treatment GUBLES Combination Tablets and GUBLES Combination OD Tablets, which was newly launched in June last year as an additional dosage form, increased, mainly as a result of promoting active medical information activities for core products. However, net sales declined due to lower sales following the launch of generic versions of the dysuria treatments for benign prostatic hyperplasia Urief Tablets and Urief OD Tablets.」
The decline in sales of existing products following the launch of generic versions of Urorec has continued, reflected in a 15.5% year-on-year decline in pharmaceutical business sales. - FY2020-Q2MaterialisedAnnual report
「Pharmaceutical business revenue was ¥26,557 million, down 11.4% year on year. Sales increased for the hyperphosphatemia treatments P-TOL Chewable Tablets and P-TOL Granules in Sachets, the overactive bladder treatment Beova Tablets, the diabetes treatment Glubes Combination Tablets and Glubes Combination OD Tablets, which were newly launched in June this year as an additional dosage form, among others, reflecting the promotion of proactive medical information activities for major products. However, revenue declined due mainly to lower sales following the launch of generic versions of Yurief Tablets and Yurief OD Tablets, treatments for urinary disorders associated with benign prostatic hyperplasia.」
A continuing decline in sales of existing products has become evident following the launch of generic versions of Urorec. - FY2020-Q1MaterialisedAnnual report
「Decline in sales resulting from the launch of generic versions of the urinary disorder treatments Urorec tablets and Urorec OD tablets for benign prostatic hyperplasia」
Generic versions were launched after Urorec’s patent expired, and a decline in sales of existing products is explicitly documented. - FY2019RestatedAnnual report
「In addition to competition from other companies’ drugs indicated for the same conditions as the drugs we sell, we face price competition from generic drugs containing the same active ingredients that are launched when patents for originator drugs expire. This competition could have a significant impact on sales of existing products.」
The potential for competition from other companies’ drugs and generic drugs to affect sales of existing products has been reconfirmed. - FY2019-Q3RestatedAnnual report
「No new business or other risks arose during the nine months ended [the current third quarter]. There have also been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
It has been reconfirmed that there have been no material changes in the risk of competition from other companies’ drugs and generic drugs. - FY2019-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
It has been reconfirmed that there have been no material changes in the risk of competition from other companies’ drugs and generic drugs. - FY2018RestatedAnnual report
「In addition to competition from other companies’ drugs indicated for the same conditions as the drugs we sell, we face price competition from generic drugs containing the same active ingredients that are launched when patents for originator drugs expire. This competition could have a significant impact on sales of existing products.」
The potential impact of competition from other companies’ drugs and generic drugs on sales of existing products has been reconfirmed. - FY2018-Q3RestatedAnnual report
「No new business or other risks arose during the nine months ended [the current third quarter]. There have also been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
It has been reconfirmed that there have been no material changes in the risk of competition from other companies’ drugs and generic drugs. - FY2018-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
It has been reconfirmed that there have been no material changes in the risk of competition from other companies’ drugs and generic drugs. - FY2017RestatedAnnual report
「In addition to competition from other companies’ drugs indicated for the same conditions as the drugs we sell, we face price competition from generic drugs containing the same active ingredients that are launched when patents for originator drugs expire. This competition could have a significant impact on sales of existing products.」
The potential impact of competition from other companies’ drugs and generic drugs on sales of existing products has been reconfirmed. - FY2016First statedAnnual report
「In addition to competition from other companies’ drugs indicated for the same conditions as the drugs we sell, we face price competition from generic drugs containing the same active ingredients that are launched when patents for originator drugs expire. This competition could have a significant impact on sales of existing products.」
Competition from drugs for the same indications and price competition from generic drugs after patent expiry are identified as risks.